Anatomy and biology: Two complementary sides of breast cancer prognostication

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4347-4348

  Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN;

AGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; DISTANT METASTASIS; EDITORIAL; HUMAN; LYMPH NODE; PATHOLOGICAL ANATOMY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENCE SCORE; RSPC SCORE; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEMIC THERAPY; TISSUE FIXATION; UNITED STATES;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN;

EID: 81755184443     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2754     Document Type: Editorial

References (10)

1. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
2. Cuzick J, Dowsett M, Wale C, et al.: Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score: Results from TransATAC. Cancer Res 69:503S, 2009 (suppl)
3. Wirapati P, Sotiriou C, Kunkel S, et al.: Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008
4. Goldstein LJ, Gray R, Badve S, et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
5. Dowsett M, Cuzick J, Wale C, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive post-menopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
6. Tang G, Cuzick J, Costantino JP, et al.: Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372, 2011
7. Wolff AC, Berry D, Carey LA, et al.: Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26:806-813, 2008 (Pubitemid 351264394)
8. Gianni L, Zambetti M, Clark K, et al.: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005 (Pubitemid 46202341)
9. Tang G, Shak S, Paik S, et al.: Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127:133-142, 2011
10. Hatzis C, Pusztai L, Valero V, et al.: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305:1873-1881, 2011